Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer

Karim Boudadi, Emmanuel S. Antonarakis

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonstrated significant survival benefits, a significant proportion of patients have primary resistance to these agents and virtually all patients develop secondary resistance. While the mechanisms of resistance to these agents are not fully understood, many hypotheses of AR-dependent and AR-independent mechanisms are emerging, including upregulation of AR and cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17), induction of AR splice variants, AR point mutations, upregulation of glucocorticoid receptor, activation of alternative oncogenic signaling pathways, neuroendocrine transformation, and immune evasion via programmed death-ligand 1 upregulation. The aim of this review is to summarize the most clinically relevant mechanisms of resistance to novel androgen-directed agents, focusing on escape from enzalutamide and abiraterone.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalClinical Medicine Insights: Oncology
StatePublished - Mar 16 2016


  • Abiraterone
  • Castration-resistant prostate cancer
  • Enzalutamide
  • Novel androgen-directed therapy
  • Resistance

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this